EHA 2011

Links to reports filed by C.A. Simoneau from EHA COngress 2011


My Report From EHA – What has me so Excited!

The Changing Landscape in CML Therapy: New Treatment Goals and Choices

Optimizing Patient Outcomes to CML Treatment in 2011


CML Education Session – T. Holyoake

CML Education Session – A. Hochhaus

CML Education Session – H. Kantarjian

CML Clinical session Saturday – 24 months follow up Nilotinib

CML Clinical session Saturday – Bosutinib follow up ( BELA trial)

CML Clinical session Saturday – BCR ABL KD Mutations

CML Clinical session Saturday – BCR ABL Fusion transcripts have prognositic values to predictMMR rates as well as OS,PFS, FFS and EFS.

CML Clinical session Saturday – cancerous inhibitor of PP2A (CIP2A)at diagnosis is a critical determinant of disease progression

CML Biology Session Saturday – PP2A as a therapeutic target

CML Biology Session Saturday – Hedgehog inhibitor combined with nilotinib

CML Biology Session Saturday – Prognosticability of enhanced Hh pathway

CML Biology Session Saturday – CIP2A inhibits PP2A and leads to BC

CML Biology Session Saturday – Prognosticability of LSC in BM in de Novo CML Patients

CML Clinical 2 Sunday – A new Prognostic Score EUTOS

CML Clinical 2 Sunday – DASISION 24 months follow up

CML Clinical 2 Sunday – Omacetaxine treatment survival compared to Historical Data

CML Clinical 2 Sunday – KIR2DS1 prognositicability

CML Clinical 2 Sunday – Stopping Dasatinib or Nilotinib in CML CP

Comments are closed .